AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 281 min read$BLCO

Bausch + Lomb raises 2026 guidance to $5.450B-$5.550B revenue and $1.090B-$1.140B adjusted EBITDA as Vision '27 momentum continues (NYSE:BLCO)

Bausch + Lomb (BLCO) raised its 2026 revenue guidance to $5.45B-$5.55B and adjusted EBITDA to $1.09B-$1.14B, citing continued momentum from its Vision '27 strategy. The company reported its fourth consecutive quarter of meeting Investor Day commitments, according to Interim CEO Thomas.

Original reporting
seekingalpha.com
Published Oct 28, 2026, 5:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLCO
Bullish
high confidence
Mentioned
$BLCO
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BLCOBullishMed
01

Why it matters

The guidance raise is a primary disclosure with material scale, likely prompting a positive price reaction.

02

Market read

Guidance lift is a significant catalyst for BLCO and may influence related ophthalmic stocks.

03

What to watch

Potential supply‑chain constraints or regulatory hurdles could temper growth.

Relevance 9/10Novelty 8/10Timing: pre‑market today

Background

Bausch + Lomb (NYSE:BLCO) announced an upward revision to its 2026 revenue and EBITDA guidance during its Q3 earnings call.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

Company raised 2026 revenue guidance to $5.45B-$5.55B and adjusted EBITDA to $1.09B-$1.14B.

Expected impact

potential upside as market prices in higher revenue outlook

Evidence & confidence

Guidance increase of several hundred million dollars is material and new, prompting traders to consider buying on the news.

Market effects

Sector

Positive outlook may lift other vision‑care and ophthalmic device peers.

Regional

U.S. healthcare sector could see modest gains.

Global

Limited to companies with exposure to eye‑care market.

Counterpoint

What could challenge this read

If guidance already priced in, the stock may face a short‑term pull‑back.

Key entities

  • Company
    Bausch + Lomb

    Vision care company listed on NYSE under ticker BLCO.

Read at source← All news

StoryBausch + Lomb posts Q3 profit, lifts 2026 revenue and EBITDA guidance

Also covered by

6 outlets

Related articles

OCT 28
$BLCOHighAI 9/10

Why is Bausch + Lomb stock surging today?

Bausch + Lomb (BLCO) stock rose 7.3% after Q3 2026 earnings beat estimates, with adjusted EPS of $0.34 vs. $0.21 expected, and revenue of $1.375B, up 7% YoY. The company raised full-year guidance for the third time, citing growth across all segments and improved profitability. The stock reached a 52-week high of $19.09.

investing.com2 min
OCT 28
$BLCOMedAI 8/10

Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb (BLCO) reported Q3 2026 earnings with 8% revenue growth to $1.375B, 34% adjusted EBITDA increase, and 23.6% margin. All segments grew: Pharmaceuticals +11%, Surgical +9%, Vision Care +6%. The company reduced net leverage to 4.1x and remains confident in meeting its 3-year plan targets.

finance.yahoo.com2 min
OCT 28
$BLCOHighAI 8/10

Bausch + Lomb Posts 7% Revenue Growth, Raises 2026 Guidance

Bausch + Lomb reported Q3 2026 revenue of $1.375B, up 7% YoY, and net income of $32M. Adjusted EBITDA was $325M, and adjusted diluted EPS was $0.34. The company raised full-year revenue guidance to $5.45B–$5.55B and adjusted EBITDA guidance to $1.09B–$1.14B. All business segments grew, with notable increases in MIEBO and LUMIFY revenues.

tradingview.com1 min